Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
GUCS 2021Cabozantinib Could Be New Standard for Papillary RCCCabozantinib outperforms the current standard of care for renal cell carcinoma (RCC), according to results from the Southwest Oncology Group 1500 trial.
Medscape Medical News, February 17, 2021
GUCS 2021'Attractive' Option for Early Metastatic SeminomaFor early-stage seminoma that metastasizes to one or two retroperitoneal lymph nodes, surgical excision is an "attractive" alternative, according to an investigator from the phase 2 SEMS trial.
Unprecedented Response Rate in Advanced Bladder CancerThe combination of enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial cancer was called
'very promising' by an expert not involved with an early phase trial.
Medscape Medical News, Feb 19, 2020
Seminoma: Risk-Adapted Strategy Could Mean Less Toxic ChemoEarly use of FDG-PET in chemotherapy can identify men with low-volume seminoma who have highly chemosensitive disease, enabling
them to safely skip the standard chemotherapy regimen with its toxicity.
Medscape Medical News, Feb 24, 2020
Hypofractionated Radiation in Prostate Cancer Stands Test of TimeFor localized prostate cancer, a hypofractionated radiotherapy regimen that cuts treatment time in half continues to have
noninferior efficacy long-term relative to a conventional radiotherapy regimen.
